Predictmedix (PMEDF) 20-F 15 Jun 23 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jan. 31, 2023 shares
Entity Addresses [Line Items]
Entity Registrant Name	PREDICTMEDIX INC.
Entity Central Index Key	0001868079
Document Type	20-F
Document Period End Date	Jan. 31, 2023
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-00000
Entity Common Stock Shares Outstanding	122,051,292
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	77 King Street W.
Entity Address, Address Line Two	Suite 3000
Entity Address, City or Town	Toronto
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1G8
Local Phone Number	889-6916
City Area Code	647
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Trading Symbol	PMED
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Accounting Standard	International Financial Reporting Standards
Title of 12(b) Security	Common
Auditor Name	Kreston GTA LLP
Auditor Location	Markham, Canada
Auditor Firm ID	6644
Canadian Securities Exchange [Member]
Entity Addresses [Line Items]
Security Exchange Name	NONE

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)	Jan. 31, 2023	Jan. 31, 2022
CURRENT
Cash and cash equivalents	$ 79,250	$ 211,302
Accounts receivable	12,506	169,545
Sales tax receivable	25,982	211,482
Prepaid expenses	19,742	49,295
Total current assets	137,480	641,624
Property and equipment	134,547	76,255
Intangible assets	445,708	518,778
TOTAL ASSETS	717,735	1,236,657
CURRENT
Accounts payable and accrued liabilities	833,254	334,452
Promissory note payable	37,870	0
Deferred revenue	0	15,220
TOTAL LIABILITIES	871,124	349,672
SHAREHOLDERS' EQUITY
Share Capital	6,256,524	5,716,131
Share subscriptions received	50,000	0
Warrant reserve	596,890	510,483
Share-based payment reserve	1,026,143	675,560
Accumulated deficit	(8,082,946)	(6,015,189)
TOTAL SHAREHOLDERS' (DEFICIENCY) EQUITY	(153,389)	886,985
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIENCY) EQUITY	$ 717,735	$ 1,236,657

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Profit or loss [abstract]
Revenue	$ 35,020	$ 134,820
Cost of revenue	8,400	50,000
Gross profit	26,620	84,820
Expenses
Administration and general	89,434	33,349
Amortization and depreciation	159,455	79,288
Audit and accounting	70,050	33,983
Consulting fees	351,875	175,746
Interest	2,870	0
Investor relations	51,936	99,307
Legal fees	94,837	192,615
Management fees	282,010	269,845
Marketing expenses	294,056	508,609
Payroll and related	115,929	165,342
Rent expense	35,901	32,147
Research and development	82,600	72,885
Share based compensation	350,583	182,996
Transfer agent and filing fees	65,576	51,244
Travel, entertainment and related	11,265	33,642
Vehicle use expenses	36,000	36,000
Total operating expenses	(2,094,377)	(1,966,998)
Income tax	0	0
Loss and comprehensive loss	(2,067,757)	(1,882,178)
Loss and comprehensive loss attributable to:
Shareholders	(2,067,757)	(1,882,178)
Non-controlling interest	$ 0	$ 0
Loss per share-Basic	$ (0.018)	$ (0.017)
Loss per share-Diluted	$ (0.018)	$ (0.017)
Weighted average number of shares outstanding-Basic	114,168,278	107,925,066
Weighted average number of shares outstanding-Diluted	114,168,278	107,925,066

Consolidated Statement Of Chang

Consolidated Statement Of Changes In Shareholders' Equity - CAD ($)	Share capital [Member]	Warrant reserve [Member]	Share-based payment reserve [Member]	Share subscriptions received [Member]	Deficit [Member]	Total
Beginning balance at Jan. 31, 2021	$ 4,031,650	$ 115,802	$ 853,848	$ 0	$ (4,133,011)	$ 868,289
Beginning balance (Shares) at Jan. 31, 2021						101,717,973
Private placement of units	695,404	394,681				$ 1,090,085
Private placement of units (Shares)						3,114,569
Share issuance costs	(3,770)					$ (3,770)
Exercise of options	956,597		(361,284)			$ 595,313
Exercise of options (Shares)						3,968,750
Share subscriptions received						$ 0
Share-based compensation			182,996			182,996
Shares issued for services	36,250					$ 36,250
Shares issued for services (Shares)						250,000
Net loss for the year					(1,882,178)	$ (1,882,178)
Ending balance at Jan. 31, 2022	5,716,131	510,483	675,560	0	(6,015,189)	$ 886,985
Ending balance (Shares) at Jan. 31, 2022						109,051,292
Private placement of units	399,961	95,039				$ 495,000
Private placement of units (Shares)						9,900,000
Share issuance costs	(24,568)	(8,632)				$ (33,200)
Share subscriptions received				50,000		50,000
Share-based compensation			350,583			350,583
Shares issued for services	165,000					$ 165,000
Shares issued for services (Shares)						3,100,000
Net loss for the year					(2,067,757)	$ (2,067,757)
Ending balance at Jan. 31, 2023	$ 6,256,524	$ 596,890	$ 1,026,143	$ 50,000	$ (8,082,946)	$ (153,389)
Ending balance (Shares) at Jan. 31, 2023						122,051,292

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
OPERATING ACTIVITIES
Net loss	$ (2,067,757)	$ (1,882,178)
Non-cash items included in net loss and other adjustments:
Amortization	159,455	79,288
Share-based compensation	350,583	182,996
Shares issued for services	165,000	36,250
Interest	2,870	0
Changes in non-cash working capital:
Sales tax receivable	185,500	(99,530)
Prepaid expenses	29,553	106,147
Accounts receivable	157,039	(169,545)
Accounts payable and accrued liabilities	498,802	199,098
Deferred revenue	(15,220)	15,220
CASH USED IN OPERATING ACTIVITIES	(534,175)	(1,532,254)
INVESTING ACTIVITIES
Purchase of property and equipment	(94,827)	(84,754)
Purchase of intangible assets	(49,850)	(333,369)
CASH USED IN INVESTING ACTIVITIES	(144,677)	(418,123)
FINANCING ACTIVITIES
Proceeds from issuance of units	495,000	1,090,085
Share issue expenses	(33,200)	(3,770)
Proceeds from promissory note	35,000	0
Share subscriptions received	50,000	0
Proceeds from exercise of options	0	595,313
CASH PROVIDED BY FINANCING ACTIVITIES	546,800	1,681,628
NET CHANGE IN CASH DURING THE YEAR	(132,052)	(268,749)
CASH, BEGINNING OF YEAR	211,302	480,051
CASH, END OF YEAR	79,250	211,302
Cash paid for interest and income taxes	0	0
Supplemental cash flow information
Shares issued for prepayment and expense for consulting fees	$ 165,000	$ 36,250

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Jan. 31, 2023
Disclosure Of Organization And Nature Of Operations [Abstract]
Organization and Nature of Operations [Text Block]	1. Organization and Nature of Operations Admiral Bay Resources Inc. ("Admiral") was incorporated in British Columbia on September 3, 1987. Effective September 23, 2019, Admiral was part of a three-cornered amalgamation among Admiral, 2693980 Ontario Inc. (a wholly owned subsidiary of Admiral) and Cultivar Holdings Ltd. (the "Transaction"). At completion of the Transaction, Admiral changed its name to Cultivar Holdings Inc. (the "Company"). On April 9, 2020, the Company completed its name change from "Cultivar Holdings Inc." to "Predictmedix Inc." (the "Name Change"). The CUSIP number assigned to the Company's common shares following the name change is CUSIP 74040L100 (ISIN CA74040L1004). In connection with the Name Change, the Company's trading symbol, as listed on the CSE and the OTCQB have also been changed from "CULT" to "PMED", and from "CVRHF" to "PMEDF", respectively. The Company's business is focused on developing artificial intelligence ("AI") powered technologies for general workplace health and safety, and for the health care industry. The Company's business is focussed on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare. The Company's corporate head office is located at 77 King Street W, Suite 3000, Toronto, Ontario, Canada, M5K 1G8.

Basis of Presentation and Going

Basis of Presentation and Going Concern	12 Months Ended
	Jan. 31, 2023
Disclosure Of Basis Of Presentation And Going Concern [Abstract]
Basis of Presentation and Going Concern [Text Block]	2. Basis of Presentation and Going Concern Basis of Preparation These consolidated financial statements have been prepared on the historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The functional currency of the Company and its subsidiaries is the Canadian dollar, which is also the Company's reporting currency. Statement of Compliance The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). Basis of Consolidation These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries; Cultivar Holdings Ltd. and Cann from the date of acquisition. All inter-company transactions and balances have been eliminated on consolidation. Going Concern Assumption These consolidated financial statements have been prepared using IFRS on a going concern basis, which presumes the realization of assets and discharge of liabilities in the normal course of business, for the next fiscal year. At January 31, 2023, the Company had cash and cash equivalents of $79,250, current liabilities in excess of current assets of $733,644 and an accumulated deficit of $8,082,946. The continuing operations of the Company are dependent on generation of revenues and profits and funding to be provided by equity investors. The Company intends to finance its future requirements through a combination of equity and/or debt issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms. This uncertainty may cast significant doubt about the ability of the Company to continue as a going concern. These consolidated financial statements do not include any adjustments to the carrying value or presentation of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. These adjustments could be material. Significant Accounting Judgments and Estimates The preparation of these consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates and assumptions. These estimates and assumptions affect the reported amounts of assets, liabilities, shareholders' equity, and the disclosure of contingent assets and liabilities, as at the date of the financial statements, and expenses for the years reported. Critical Judgements The preparation of these consolidated financial statements requires management to make judgements regarding the going concern of the Company (discussed above). Key Sources of Estimation Uncertainty Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting the consolidated financial statements include: Share-based payments Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them. Deferred tax assets & liabilities The estimation of income taxes includes evaluating the recoverability of deferred tax assets and liabilities based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probable that some or all of the deferred income tax assets and liabilities will not be realized. The ultimate realization of deferred tax assets and liabilities is dependent upon the generation of future taxable income. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets or liabilities, and deferred income tax provisions or recoveries could be affected. Key Sources of Estimation Uncertainty (Cont'd) Useful life of property and equipment Property and equipment is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated physical life of the asset, the potential for technological obsolescence, and regulations. Useful life of intangible assets The intangible asset is amortized over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated life of the asset, the potential for technological obsolescence Impairment of long lived assets The Company assesses impairment of non-financial assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions. Provision for expected credit losses of trade receivables The Company assesses the expected credit losses (ECL) on accounts receivable on their sole customer considering the unique circumstances and ongoing communication. There is limited historical data of repayments and no credit rating available. While the receivables are overdue, based on the constant contact, agreement with the customer, and written confirmation received on agreed balances the Company has determined the ECL for this customer to be zero. Approval of the consolidated financial statements These consolidated financial statements were authorized for issuance by the Board of Directors on May 31, 2023.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jan. 31, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. Cash Cash comprises of cash held at banks and amounts held in trust. The majority of the Company's cash is held in a major financial institution. The Company does not invest in any asset-backed deposits or investments. Income taxes Income tax on profit or loss for the period comprises of current and deferred tax. Current tax is the expected tax paid or payable on the taxable income for the period, using tax rates enacted or substantively enacted at the statement of financial position date, and any adjustment to tax paid or payable in respect of previous periods. Deferred tax is recorded by providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The effect on deferred tax assets and liabilities of a change in income tax rates is recognized in the period that includes the date of the enactment or substantive enactment of the change. Deferred tax assets and liabilities are presented separately except where there is a right of set-off within fiscal jurisdictions Foreign currency translation Foreign currency transactions are translated into Canadian dollars as follows: At the transaction date, each asset, liability, revenue and expense denominated in a foreign currency is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the period-end date, unsettled monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at the year-end date and the related translation differences are recognized in net loss. Non-monetary assets and liabilities that are measured at historical cost are translated into Canadian dollars by using the exchange rate in effect at the date of the initial transaction and are not subsequently restated. Non-monetary assets and liabilities that are measured at fair value or a revalued amount are translated into Canadian dollars by using the exchange rate in effect at the date the value is determined, and the related translation differences are recognized in net loss or other comprehensive loss consistent with where the gain or loss on the underlying non-monetary asset or liability has been recognized. Share Capital Common shares and warrants are classified as shareholders' equity. Incremental costs directly attributable to the issue of common shares are recognized as a reduction of shareholders' equity, net of tax. The Company has adopted a relative fair value method with respect to the measurement of common shares and warrants issued as private placement units. The relative fair value method allocates value to each component on a pro-rata basis, based on the fair value of the components calculated independently of one another. The Company considers the market value of the common shares issued as fair value and measures the fair value of the warrant component of the unit using the Black-Scholes option pricing model. The unit value is then allocated, pro-rata, between the two components, with fair value attributed to the warrants being recorded to the Company's warrant reserve. Loss per share Loss per share is computed by dividing the net loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted loss per common share is computed by dividing the net loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. Share-based payments The Company grants stock options to buy common shares of the Company to consultants and service providers. The Company recognizes share-based compensation expense based on the estimated fair value of the options. A fair value measurement is made for each vesting instalment within each option grant and is determined using the Black-Scholes option-pricing model. The fair value of the options is recognized over the vesting period of the options granted as both share-based compensation expense and reserves. This includes a forfeiture estimate, which is revised for actual forfeitures in subsequent periods. The reserves account is subsequently reduced if the options are exercised, and the amount initially recorded is then credited to capital stock. In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of the goods or services received. Property and equipment Property and equipment is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of the item of property and equipment consists of the purchase price, and any costs directly attributable to bringing the asset to the location and condition necessary for its intended use. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the consolidated statement of loss and comprehensive loss. The cost of repairs and maintenance is expensed as incurred. The Company amortizes its property and equipment using the following rates: Equipment Intangible assets Intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is recorded on a straight-line basis over the estimated useful life of the asset acquired, which varies depending on the nature of the intangible asset. Intangible assets are amortized from the date when they are available for use. The estimated useful life is reviewed at the end of each reporting period with the effect of any changes in estimate being accounted for on a prospective basis. Internally incurred development costs are recognized as intangible assets when the following criteria are met: a) b) c) d) e) f) Intangible assets may relate to the Company's external development expenditures in relation to intellectual property development. Development expenditures that do not meet these criteria are recognized as an expense as incurred. Intangible assets with definite lives are assessed for impairment whenever there is an indication that the intangible asset may be impaired. These intangible assets will be amortized when they are ready for use. The amortization period and the amortization method are reviewed at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates on a prospective basis. Impairment of non-financial assets The carrying amount of the Company's assets is reviewed for an indication of impairment at the end of each reporting period. If an indication of impairment exists, the Company makes an estimate of the asset's recoverable amount. Individual assets are grouped for impairment assessment purposes at the lowest level at which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. Recoverable amount of an asset group is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are adjusted for the risks specific to the asset group and are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money. Where the carrying amount of an asset group exceeds its recoverable amount, the asset group is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in profit or loss. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognized. Financial Instruments Financial assets and financial liabilities are recognized on the consolidated statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument. The following is the Company's accounting policy for financial instruments under IFRS 9: Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of loss and comprehensive loss in the period in which they arise. Debt investments at FVOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. The Company determines the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument. Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data. The Company's financial assets and liabilities are carried at amortized cost and belong to Level 2 of the fair value hierarchy. During the year ended January 31, 2023 there were no transfers between the level of fair value hierarchy. The carrying amounts of these financial instruments are approximately estimate their fair values. Impairment of financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in a separate line item. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Revenue recognition Revenue is recognized at an amount that reflects the expected consideration receivable in exchange for transferring goods or services to a customer, applying the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) the entity satisfies a performance obligation Under IFRS 15, the Company classified its revenue as being principally derived from the following source: Screening services revenue on deployment of safe entry stations for use of the Company's technology. Revenue from the sale of screening services is recognized based on the transaction price. Upfront fees as set-up fees are included in the transaction price and allocated to the performance obligation in the contract. Revenue is recognized as the performance obligations are satisfied. Segments reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Company's chief operating decision maker (CODM). The CODM has been identified as the Board of Directors of the Company. For management purposes, the Company uses the same measurement policies as those used in its financial statements. The CODM evaluates the performance of each segment based on net profit (loss). The Company operates in a single reportable operating segment. New standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendments: • clarify that the classification of liabilities as current or non-current should only be based on rights that are in place "at the end of the reporting period" • clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability • make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability. This amendment is effective for annual periods beginning on or after January 1, 2024. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

Property and Equipment

Property and Equipment	12 Months Ended
	Jan. 31, 2023
Property, plant and equipment [abstract]
Property and Equipment [Text Block]	4. Property and Equipment Equipment Total Cost Balance as at January 31, 2021 $ 13,368 $ 13,368 Additions 84,755 84,755 Balance as at January 31, 2022 $ 98,123 $ 98,123 Additions 94,827 94,827 Balance as at January 31, 2023 $ 192,950 $ 192,950 Accumulated Depreciation Balance as at January 31, 2021 $ 5,180 $ 5,180 Depreciation 16,688 16,688 Balance as at January 31, 2022 $ 21,868 $ 21,868 Depreciation 36,535 36,535 Balance as at January 31, 2023 $ 58,403 $ 58,403 Net Carrying Amounts As at January 31, 2023 $ 134,547 $ 134,547 As at January 31, 2022 $ 76,255 $ 76,255

Intangible Assets

Intangible Assets	12 Months Ended
	Jan. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
Intangible Assets [Text Block]	5. Intangible Assets a) On July 21, 2020, the Company completed the acquisition of MobileWellbeing ("MWB"), an innovative, feature rich, Telemedicine Remote Patient Monitoring platform that will integrate with the Company's Artificial Intelligence ("AI") driven rapid screening system for infectious diseases, including COVID-19. The consideration for the purchase was satisfied by payment in cash for $25,000, issuance of 20,000 shares and additional 30,000 shares that were issued on the 90 th The acquisition has contingent considerations and royalty payments on achievement of certain milestones. The Company shall pay royalty of 20 percent of gross sales from the first $2.5 million in sales generated exclusively from the MWB platform. In addition, the Company is obligated to issue an additional 200,000 common shares commencing with the release of the initial version of the MWB platforms to the market and achievement of sales related milestones. Contingent consideration in an asset acquisition was discussed at the March 2016 IFRS Interpretations Committee (IFRIC) meeting. An accounting policy choice exists, therefore an entity may recognize a liability for the expected variable payments at the time control of the underlying asset is obtained or they may only recognize such a liability as the related activity that gives rise to the variability occurs. The Company has opted to recognize the liability only when the related activity that gives rise to the variability occurs. Consideration Cash consideration on closing $ 25,000 Issued shares (50,000 shares issued at $1.06/share) 53,000 $ 78,000 Purchase Price allocation Intangible asset- MWB remote patient monitoring platform $ 78,000 $ 78,000 b) infectious disease symptom screening solution ("IDSS") The Company has commenced amortization on the intangible assets on a straight line basis over the useful life estimated to be for 5 years. The Company's intangible assets are comprised of the following: MWB IDSS Total Cost Balance at January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Additions 46,591 286,778 333,369 Balance at January 31, 2022 $ 138,561 $ 442,818 $ 581,379 Additions - 49,850 49,850 Balance at January 31, 2023 $ 138,561 $ 492,668 $ 631,229 Accumulated amortization: Balance as at January 1, 2021 $ - $ - $ - Amortization 18,990 43,611 62,601 Balance as at January 31, 2022 $ 18,990 $ 43,611 $ 62,601 Amortization 27,708 95,212 122,920 Balance as at January 31, 2023 $ 46,698 $ 138,823 $ 185,521 Net Book Value Balance, January 31, 2023 $ 91,863 $ 353,845 $ 445,708 Balance, January 31, 2022 $ 119,571 $ 399,207 $ 518,778

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Jan. 31, 2023
Disclosure Of Share Based Compensation [Abstract]
Stock-based compensation [Text Block]	6. Stock-based Compensation The Company has established a stock option plan whereby officers, directors, employees and service providers may be granted options to purchase common shares at a fixed price. Vesting and expiry provisions are determined at the date of grant. The plan provides for the issuance of stock options to acquire up to 10% of the Company's issued and outstanding capital. The plan is a rolling plan as the number of shares reserved for issuance pursuant to the grant of stock options will increase as the Company's issued and outstanding share capital increases. Year ended January 31, 2023 (a) (b) (c) (d) Risk free rate 4.00% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 141% Expected life 4 years Unvested stock-based compensation expense as of January 31, 2023 $ - As of January 31, 2023, there was $nil of unvested stock-based compensation expense. Year ended January 31, 2022 (a) (b) (c) Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 134.3% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2022 $ 1,834 During the year ended January 31, 2022, the Company expensed $50,675 relating to the vesting of options, resulting in unvested stock- based compensation expense of $1,834 as of January 31, 2022. (d) Risk free rate 0.32% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 146.38% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 6,778 During the year ended January 31, 2022, the Company expensed $48,672 relating to the vesting of options, resulting in unvested stock- based compensation expense of $6,778 as of January 31, 2022. (e) Risk free rate 0.38% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 131.33% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 7,826 During the year ended January 31, 2022, the Company expensed $30,445 relating to the vesting of options, resulting in unvested stock- based compensation expense of $7,826 as of January 31, 2022. As of January 31, 2022, there was a total of $16,438 of unvested stock-based compensation expense. Continuity of the Company's options is as follows: Number of Options Weighted Average Exercise Price Outstanding, January 31, 2021 9,095,000 $ 0.18 Granted 750,000 $ 0.32 Expired (4,776,250 ) $ 0.17 Exercised (3,968,750 ) $ 0.15 Outstanding, January 31, 2022 1,100,000 $ 0.42 Granted 10,000,000 $ 0.05 Expired (70,000 ) $ 0.54 Expired (200,000 ) $ 0.54 Expired (250,000 ) $ 0.36 Expired (250,000 ) $ 0.35 Outstanding January 31, 2023 10,330,000 $ 0.06 As at January 31, 2023, the Company had the following share purchase options outstanding and exercisable: Number of options Outstanding Exercisable Exercise Price Remaining Life (Years) Expiry Date 80,000 80,000 $ 1.02 2.46 July 17, 2025 250,000 250,000 $ 0.25 0.50 July 30, 2023 10,000,000 10,000,000 $ 0.05 3.95 January 13, 2027 10,330,000 10,330,000 $ 0.06 3.86

Capital Stock

Capital Stock	12 Months Ended
	Jan. 31, 2023
Disclosure of classes of share capital [abstract]
Capital Stock [Text Block]	7. Capital Stock The Company is authorized to issue the following shares: Unlimited number of common shares without par value a) Common shares The holders of common shares are entitled to receive dividends and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regards to the Company's residual assets. At January 31, 2023, the Company has 122,051,292 common shares issued and outstanding. b) Share issuances During the year ended January 31, 2023 On August 22, 2022, the Company closed the first tranche of a private placement of 8,300,000 units at $0.05 per unit for a consideration of $415,000. Each unit is comprised of one common share and one-half common share purchase warrant, with each whole warrant exercisable into a common share of the Company at an exercise price of $0.10 per share for a period of 24 months. The Black-Scholes option pricing model was used to determine the fair value of the warrants using the following weight average assumptions: Expected dividend yield of 0%; risk free interest rate of 3.49%; expected volatility of 101.42%; expected life of 2 years. The relative fair value of the 4,150,000 warrants has been valued at $83,830 and common shares at $331,170. In connection with this private placement, the Company incurred $33,200 in share issuance costs. On August 22, 2022, 1,200,000 shares were fair valued at $72,000 and issued for services. On September 30, 2022, 200,000 shares were fair valued at $12,000 and issued for services. On October 24, 2022, 300,000 shares were fair valued at $15,000 and issued for services. On October 31, 2022, 200,000 shares were fair valued at $9,000 and issued for services. On November 1, 2022, the Company closed the final tranche of a private placement of 1,600,000 units at $0.05 per unit for a consideration of $80,000. Each unit is comprised of one common share and one-half common share purchase warrant, with each whole warrant exercisable into a common share of the Company at an exercise price of $0.10 per share for a period of 24 months. The Black-Scholes option pricing model was used to determine the fair value of the warrants using the following weight average assumptions: Expected dividend yield of 0%; risk free interest rate of 3.91%; expected volatility of 102.4%; expected life of 2 years. The relative fair value of the 800,000 warrants has been valued at $11,208 and common shares at $68,792. On November 7, 2022, 1,000,000 shares were fair valued at $50,000 and issued for services. On November 30, 2022, 200,000 shares were fair valued at $7,000 and issued for services. During the year the Company received $50,000 being subscription for 1,000,000 units (the "Units") at a price of $0.05 per unit. (See subsequent event note 17) During the year ended January 31, 2022 On March 5, 2021, the Company closed a private placement of 3,114,569 units at $0.35 per unit for a consideration of $1,090,085. Each unit is comprised of one common share and one common share purchase warrant, with each warrant exercisable into a common share of the Company at an exercise price of $0.50 per share for a period of 24 months. The Black-Scholes option pricing model was used to determine the fair value of the warrants using the following weight average assumptions: Expected dividend yield of 0%; risk free interest rate of 0.29%; expected volatility of 131%; expected life of 2 years. The relative fair value of the warrants has been valued at $394,681 and common shares at $695,404. In connection with this private placement, the Company incurred $3,770 in share issuance costs. 3,968,750 shares were issued upon exercise of 3,968,750 options at a price of $0.15 per share for total gross proceeds of $595,313. An amount of $361,284 was reclassed from share-based payment reserve to share capital. 250,000 shares were fair valued at $36,250 and issued for services. c) Warrants Continuity of the Company's warrants is as follows: Number of Warrants Weighted Average Exercise Price Outstanding, January 31, 2021 1,548,000 $ 0.50 Issued 3,114,569 $ 0.50 Expired (1,548,000 ) $ 0.50 Outstanding, January 31, 2022 3,114,569 $ 0.50 Issued 4,150,000 $ 0.10 Issued 800,000 $ 0.10 Expired - - Outstanding, January 31, 2023 8,064,569 $ 0.25 As at January 31, 2023, the Company had the following warrants outstanding: Outstanding Exercise Price Remaining Life (Years) Expiry Date 3,114,569 $0.50 0.09 March 5, 2023 4,150,000 $0.10 1.56 August 22, 2024 800,000 $0.10 1.75 November 1, 2024 8,064,569 $0.25 1.01

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jan. 31, 2023
Disclosure of transactions between related parties [abstract]
Related Party Transactions [Text Block]	8. Related Party Transactions Related parties include key management personnel, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Key management of the Company are members of the Board of Directors, the Chief Executive Officer ("CEO"), the Chief Financial Officer ("CFO") and the Chief Operating Officer ("COO"). Transactions with key management personnel not disclosed elsewhere in the financial statements include the following: Year ended January 31, 2023 Year ended January 31, 2022 Management fees to the CEO $ 120,000 $ 109,500 Management fees to the COO 102,000 92,000 Management fees to the CFO 60,010 68,345 Total Management fees $ 282,010 $ 269,845 Vehicle expense to the CEO 18,000 18,000 Vehicle expenses to the COO 18,000 18,000 Rent to the CEO included in rent expense 24,000 28,500 $ 342,010 $ 334,345 During the year ended January 31, 2023, the Company paid $149,000 (January 31, 2022: $127,000) being marketing and other expenses to companies controlled by the close family member of the CEO. As of January 31, 2023, there was $197,108 due to related parties (January 31, 2022- $nil). During the year ended January 31, 2023, there was $12,995 advanced to the CEO to meet Company expenses (2022: $12,995) and included in prepaid expenses.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 31, 2023
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies [Text Block]	9. Commitments and Contingencies Effective July 1, 2022, the Company signed a new two-year contract with a corporation owned and controlled by the CEO to pay monthly compensation of $10,000 for CEO services. In addition, the Company is obligated to pay monthly rent of $2,000 and an additional $1,500 for the use of a personal vehicle. Effective July 1, 2022, the Company signed a two-year contract with a corporation owned and controlled by the COO to pay monthly compensation of $8,500 for COO services. In addition, the Company is obligated to pay an additional $1,500 for the use of a personal vehicle.

Financial Instruments

Financial Instruments	12 Months Ended
	Jan. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments [Text Block]	10. Financial Instruments The Company's financial assets and liabilities are carried at amortized cost and belong to Level 2 of the fair value hierarchy. During the year ended January 31, 2023 there were no transfers between the level of fair value hierarchy. The carrying amounts of these financial instruments are approximately estimate their fair values due to their short-term nature. Financial risk management and objectives The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk. The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. Where material, these risks are reviewed and monitored by the Board of Directors. Credit risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk as during the year ended January 31, 2023, one customer represented 95% of the total revenue and represented 86% of the total accounts receivable. (January 31, 2022: one customer represented 100% of total revenue and 100% of total receivable) Liquidity risk Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flows primarily from its financing activities. The Company manages its liquidity needs by carefully monitoring scheduled costs. Liquidity is measured in various time bands, on day to day and week-to-week basis, as well as on long term liquidity needs over 180 day to 360 day look out periods. Funding for long term liquidity needs is based on the ability of the Company to successfully complete private placements. The carrying amount of the company's financial liabilities approximates their contractual undiscounted cash flows and due within 0 to 12 month as of January 31, 2023 and January 31, 2022. As at January 31, 2023, the Company had cash and cash equivalents of $79,250 to settle current liabilities of $871,124 (as at January 31, 2022: cash and cash equivalents of $211,302 to settle current liabilities of $349,672. Market Risk Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates. (a) Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk. (b) Price risk The Company is not exposed to significant price risk as it does not possess investments in publicly traded securities. (c) Currency risk Currency risk is the risk that the fair value of future cash flows of a financial instrument denominated in a foreign currency will fluctuate because of changes in foreign exchange rates. The Company is not exposed to any significant currency risk.

Capital Management

Capital Management	12 Months Ended
	Jan. 31, 2023
Disclosure Of Capital Management [Abstract]
Capital Management [Text Block]	11. Capital Management The Company considers its capital to be shareholders' equity, which is comprised of share capital and deficit, which as at January 31, 2023 was a deficiency of $153,389. The Company's capital structure is adjusted based on the funds available to the Company such that it may continue to seek new opportunities. The Board of Directors does not establish quantitative return on capital criteria, but rather relies on the expertise of management and other professionals to sustain future development of the business. The sources of future funds presently available to the Company are through the sale of equity capital or debt of the Company. The ability of the Company to arrange such financing in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Company. There can be no assurance that the Company will be successful in its efforts to arrange additional financing, if needed, on terms satisfactory to the Company. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company is not subject to externally imposed capital restrictions.

Business Segment and Concentrat

Business Segment and Concentration	12 Months Ended
	Jan. 31, 2023
Disclosure of operating segments [abstract]
Business Segment and Concentration [Text Block]	12. Business Segment and Concentration The Company is currently focused on artificial intelligence ("AI") technologies which are targeting two specific areas: 1) workplace health and safety and 2) healthcare. All assets are located in Canada except property and equipment for $53,374 (prior year $76,255) which is located in India. During the year ended January 31, 2023, one customer represented 95% of the total revenue and represented 86% of the total accounts receivable. (January 31, 2022: one customer represented 100% of total revenue and 100% of total receivable)

Income Taxes

Income Taxes	12 Months Ended
	Jan. 31, 2023
Major components of tax expense (income) [abstract]
Income Taxes [Text Block]	13. Income Taxes The following is a reconciliation of income taxes attributable to operations computed at the statutory tax rates to income tax recovery. January 31, 2023 January 31, 2022 Loss for the period $ (2,067,757 ) $ (1,882,178 ) Tax rate 27% 27% Expected income tax recoverable at statutory rate (558,000 ) (508,000 ) Change due to acquisition, tax rates, and other - - Non-deductible items 95,000 54,000 Share issuance costs (7,000 ) (1,000 ) Expired non-capital losses - Change in unrecognized deductible temporary differences 470,000 455,000 Total income tax recovery $ - $ - Deferred tax assets The significant components of the Company's deferred tax assets that have not been included on the consolidated statement of financial position are as follows: January 31, 2023 January 31, 2022 Non-capital losses available for future period $ 2,159,000 $ 1,821,000 Share issuance costs 11,000 13,000 Property equipment and intangible assets 45,000 22,000 Total deferred tax assets 2,215,000 1,856,000 Less: Unrecognized deferred tax assets (2,215,000 ) (1,856,000 ) Net deferred tax assets $ - $ - The significant components of the Company's unrecognized temporary differences and tax losses are as follows: January 31, 2023 Expiry Date January 31, 2022 Non-capital losses $ 7,995,200 2027 - 2043 6,745,000 Share issuance costs $ 41,000 2043 - 2047 47,000 Property equipment and intangible assets $ 168,000 No expiry 84,000 Tax attributes are subject to review and potential adjustment by tax authorities.

Promissory note

Promissory note	12 Months Ended
	Jan. 31, 2023
Borrowing costs [abstract]
Promissory note [Text Block]	14. Promissory note On December 12, 2023, the Company availed a loan for $35,000 repayable in four months by issue of a promissory note. The loan carries an interest of 59.9%pa. The Company accrued interest of $2,870 as of January 31, 2023. This loan is not repaid as of January 31, 2023.

Subsequent events

Subsequent events	12 Months Ended
	Jan. 31, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events [Text Block]	15. Subsequent events a) b) c) d)

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 31, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Cash [Policy Text Block]	Cash Cash comprises of cash held at banks and amounts held in trust. The majority of the Company's cash is held in a major financial institution. The Company does not invest in any asset-backed deposits or investments.
Income taxes [Policy Text Block]	Income taxes Income tax on profit or loss for the period comprises of current and deferred tax. Current tax is the expected tax paid or payable on the taxable income for the period, using tax rates enacted or substantively enacted at the statement of financial position date, and any adjustment to tax paid or payable in respect of previous periods. Deferred tax is recorded by providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The effect on deferred tax assets and liabilities of a change in income tax rates is recognized in the period that includes the date of the enactment or substantive enactment of the change. Deferred tax assets and liabilities are presented separately except where there is a right of set-off within fiscal jurisdictions
Foreign currency translation [Policy Text Block]	Foreign currency translation Foreign currency transactions are translated into Canadian dollars as follows: At the transaction date, each asset, liability, revenue and expense denominated in a foreign currency is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the period-end date, unsettled monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at the year-end date and the related translation differences are recognized in net loss. Non-monetary assets and liabilities that are measured at historical cost are translated into Canadian dollars by using the exchange rate in effect at the date of the initial transaction and are not subsequently restated. Non-monetary assets and liabilities that are measured at fair value or a revalued amount are translated into Canadian dollars by using the exchange rate in effect at the date the value is determined, and the related translation differences are recognized in net loss or other comprehensive loss consistent with where the gain or loss on the underlying non-monetary asset or liability has been recognized.
Share Capital [Policy Text Block]	Share Capital Common shares and warrants are classified as shareholders' equity. Incremental costs directly attributable to the issue of common shares are recognized as a reduction of shareholders' equity, net of tax. The Company has adopted a relative fair value method with respect to the measurement of common shares and warrants issued as private placement units. The relative fair value method allocates value to each component on a pro-rata basis, based on the fair value of the components calculated independently of one another. The Company considers the market value of the common shares issued as fair value and measures the fair value of the warrant component of the unit using the Black-Scholes option pricing model. The unit value is then allocated, pro-rata, between the two components, with fair value attributed to the warrants being recorded to the Company's warrant reserve.
Loss per share [Policy Text Block]	Loss per share Loss per share is computed by dividing the net loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted loss per common share is computed by dividing the net loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted.
Share-based payments [Policy Text Block]	Share-based payments The Company grants stock options to buy common shares of the Company to consultants and service providers. The Company recognizes share-based compensation expense based on the estimated fair value of the options. A fair value measurement is made for each vesting instalment within each option grant and is determined using the Black-Scholes option-pricing model. The fair value of the options is recognized over the vesting period of the options granted as both share-based compensation expense and reserves. This includes a forfeiture estimate, which is revised for actual forfeitures in subsequent periods. The reserves account is subsequently reduced if the options are exercised, and the amount initially recorded is then credited to capital stock. In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of the goods or services received.
Property and equipment: [Policy Text Block]	Property and equipment Property and equipment is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of the item of property and equipment consists of the purchase price, and any costs directly attributable to bringing the asset to the location and condition necessary for its intended use. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the consolidated statement of loss and comprehensive loss. The cost of repairs and maintenance is expensed as incurred. The Company amortizes its property and equipment using the following rates: Equipment
Intangible assets [Policy Text Block]	Intangible assets Intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is recorded on a straight-line basis over the estimated useful life of the asset acquired, which varies depending on the nature of the intangible asset. Intangible assets are amortized from the date when they are available for use. The estimated useful life is reviewed at the end of each reporting period with the effect of any changes in estimate being accounted for on a prospective basis. Internally incurred development costs are recognized as intangible assets when the following criteria are met: a) b) c) d) e) f) Intangible assets may relate to the Company's external development expenditures in relation to intellectual property development. Development expenditures that do not meet these criteria are recognized as an expense as incurred. Intangible assets with definite lives are assessed for impairment whenever there is an indication that the intangible asset may be impaired. These intangible assets will be amortized when they are ready for use. The amortization period and the amortization method are reviewed at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates on a prospective basis.
Impairment of non-financial assets [Policy Text Block]	Impairment of non-financial assets The carrying amount of the Company's assets is reviewed for an indication of impairment at the end of each reporting period. If an indication of impairment exists, the Company makes an estimate of the asset's recoverable amount. Individual assets are grouped for impairment assessment purposes at the lowest level at which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. Recoverable amount of an asset group is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are adjusted for the risks specific to the asset group and are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money. Where the carrying amount of an asset group exceeds its recoverable amount, the asset group is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in profit or loss. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognized.
Financial Instruments [Policy Text Block]	Financial Instruments Financial assets and financial liabilities are recognized on the consolidated statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument. The following is the Company's accounting policy for financial instruments under IFRS 9: Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of loss and comprehensive loss in the period in which they arise. Debt investments at FVOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. The Company determines the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument. Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data. The Company's financial assets and liabilities are carried at amortized cost and belong to Level 2 of the fair value hierarchy. During the year ended January 31, 2023 there were no transfers between the level of fair value hierarchy. The carrying amounts of these financial instruments are approximately estimate their fair values. Impairment of financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in a separate line item. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Revenue recognition Revenue is recognized at an amount that reflects the expected consideration receivable in exchange for transferring goods or services to a customer, applying the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) the entity satisfies a performance obligation Under IFRS 15, the Company classified its revenue as being principally derived from the following source: Screening services revenue on deployment of safe entry stations for use of the Company's technology. Revenue from the sale of screening services is recognized based on the transaction price. Upfront fees as set-up fees are included in the transaction price and allocated to the performance obligation in the contract. Revenue is recognized as the performance obligations are satisfied. Segments reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Company's chief operating decision maker (CODM). The CODM has been identified as the Board of Directors of the Company. For management purposes, the Company uses the same measurement policies as those used in its financial statements. The CODM evaluates the performance of each segment based on net profit (loss). The Company operates in a single reportable operating segment.
New standards not yet adopted [Policy Text Block]	New standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendments: • clarify that the classification of liabilities as current or non-current should only be based on rights that are in place "at the end of the reporting period" • clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability • make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability. This amendment is effective for annual periods beginning on or after January 1, 2024. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jan. 31, 2023
Property, plant and equipment [abstract]
Disclosure of property and equipment [Table Text Block]	Equipment Total Cost Balance as at January 31, 2021 $ 13,368 $ 13,368 Additions 84,755 84,755 Balance as at January 31, 2022 $ 98,123 $ 98,123 Additions 94,827 94,827 Balance as at January 31, 2023 $ 192,950 $ 192,950 Accumulated Depreciation Balance as at January 31, 2021 $ 5,180 $ 5,180 Depreciation 16,688 16,688 Balance as at January 31, 2022 $ 21,868 $ 21,868 Depreciation 36,535 36,535 Balance as at January 31, 2023 $ 58,403 $ 58,403 Net Carrying Amounts As at January 31, 2023 $ 134,547 $ 134,547 As at January 31, 2022 $ 76,255 $ 76,255

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jan. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
Disclosure of detailed information about purchase price allocation of intangible assets [Table Text Block]	Consideration Cash consideration on closing $ 25,000 Issued shares (50,000 shares issued at $1.06/share) 53,000 $ 78,000 Purchase Price allocation Intangible asset- MWB remote patient monitoring platform $ 78,000 $ 78,000
Disclosure of detailed information about intangible assets [Table Text Block]	MWB IDSS Total Cost Balance at January 31, 2021 $ 91,970 $ 156,040 $ 248,010 Additions 46,591 286,778 333,369 Balance at January 31, 2022 $ 138,561 $ 442,818 $ 581,379 Additions - 49,850 49,850 Balance at January 31, 2023 $ 138,561 $ 492,668 $ 631,229 Accumulated amortization: Balance as at January 1, 2021 $ - $ - $ - Amortization 18,990 43,611 62,601 Balance as at January 31, 2022 $ 18,990 $ 43,611 $ 62,601 Amortization 27,708 95,212 122,920 Balance as at January 31, 2023 $ 46,698 $ 138,823 $ 185,521 Net Book Value Balance, January 31, 2023 $ 91,863 $ 353,845 $ 445,708 Balance, January 31, 2022 $ 119,571 $ 399,207 $ 518,778

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Jan. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of number and weighted average exercise prices of share options [Table Text Block]	Number of Options Weighted Average Exercise Price Outstanding, January 31, 2021 9,095,000 $ 0.18 Granted 750,000 $ 0.32 Expired (4,776,250 ) $ 0.17 Exercised (3,968,750 ) $ 0.15 Outstanding, January 31, 2022 1,100,000 $ 0.42 Granted 10,000,000 $ 0.05 Expired (70,000 ) $ 0.54 Expired (200,000 ) $ 0.54 Expired (250,000 ) $ 0.36 Expired (250,000 ) $ 0.35 Outstanding January 31, 2023 10,330,000 $ 0.06
Disclosure of number and weighted average remaining contractual life of outstanding share options [Table Text Block]	Number of options Outstanding Exercisable Exercise Price Remaining Life (Years) Expiry Date 80,000 80,000 $ 1.02 2.46 July 17, 2025 250,000 250,000 $ 0.25 0.50 July 30, 2023 10,000,000 10,000,000 $ 0.05 3.95 January 13, 2027 10,330,000 10,330,000 $ 0.06 3.86
Stock Options Granted on January 13, 2023 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 4.00% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 141% Expected life 4 years Unvested stock-based compensation expense as of January 31, 2023 $ -
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.26% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 134.3% Expected life 1 year Unvested stock-based compensation expense as of January 31, 2022 $ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.32% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 146.38% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	Risk free rate 0.38% Expected dividends 0% Expected forfeiture rate 0% Expected volatility 131.33% Expected life 1.5 years Unvested stock-based compensation expense as of January 31, 2022 $ 7,826

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Jan. 31, 2023
Disclosure of classes of share capital [abstract]
Disclosure of continuity of warrants [Table Text Block]	Number of Warrants Weighted Average Exercise Price Outstanding, January 31, 2021 1,548,000 $ 0.50 Issued 3,114,569 $ 0.50 Expired (1,548,000 ) $ 0.50 Outstanding, January 31, 2022 3,114,569 $ 0.50 Issued 4,150,000 $ 0.10 Issued 800,000 $ 0.10 Expired - - Outstanding, January 31, 2023 8,064,569 $ 0.25
Disclosure of number, exercise price and remaining life of outstanding warrants [Table Text block]	Outstanding Exercise Price Remaining Life (Years) Expiry Date 3,114,569 $0.50 0.09 March 5, 2023 4,150,000 $0.10 1.56 August 22, 2024 800,000 $0.10 1.75 November 1, 2024 8,064,569 $0.25 1.01

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jan. 31, 2023
Disclosure of transactions between related parties [abstract]
Disclosure of transactions with key management personnel [Table Text Block]	Year ended January 31, 2023 Year ended January 31, 2022 Management fees to the CEO $ 120,000 $ 109,500 Management fees to the COO 102,000 92,000 Management fees to the CFO 60,010 68,345 Total Management fees $ 282,010 $ 269,845 Vehicle expense to the CEO 18,000 18,000 Vehicle expenses to the COO 18,000 18,000 Rent to the CEO included in rent expense 24,000 28,500 $ 342,010 $ 334,345

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 31, 2023
Major components of tax expense (income) [abstract]
Disclosure of reconciliation of provision for income taxes [Table Text Block]	January 31, 2023 January 31, 2022 Loss for the period $ (2,067,757 ) $ (1,882,178 ) Tax rate 27% 27% Expected income tax recoverable at statutory rate (558,000 ) (508,000 ) Change due to acquisition, tax rates, and other - - Non-deductible items 95,000 54,000 Share issuance costs (7,000 ) (1,000 ) Expired non-capital losses - Change in unrecognized deductible temporary differences 470,000 455,000 Total income tax recovery $ - $ -
Disclosure of deferred taxes [Table Text Block]	January 31, 2023 January 31, 2022 Non-capital losses available for future period $ 2,159,000 $ 1,821,000 Share issuance costs 11,000 13,000 Property equipment and intangible assets 45,000 22,000 Total deferred tax assets 2,215,000 1,856,000 Less: Unrecognized deferred tax assets (2,215,000 ) (1,856,000 ) Net deferred tax assets $ - $ -
Disclosure of unrecognized temporary differences and tax losses [Table Text Block]	January 31, 2023 Expiry Date January 31, 2022 Non-capital losses $ 7,995,200 2027 - 2043 6,745,000 Share issuance costs $ 41,000 2043 - 2047 47,000 Property equipment and intangible assets $ 168,000 No expiry 84,000

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern (Narrative) (Details) - CAD ($)	Jan. 31, 2023	Jan. 31, 2022
Disclosure Of Basis Of Presentation And Going Concern [Abstract]
Cash and cash equivalents	$ 79,250	$ 211,302
Current liabilities in excess of current assets	733,644
Accumulated deficit	$ 8,082,946	$ 6,015,189

Significant Accounting Polici_3

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Jan. 31, 2023
Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment amortization rate	30%

Property and Equipment (Disclos

Property and Equipment (Disclosure of property and equipment) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	$ 76,255
Ending Balance	134,547	$ 76,255
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	98,123	13,368
Additions	94,827	84,755
Ending Balance	192,950	98,123
Accumulated Amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	(21,868)	(5,180)
Depreciation	(36,535)	(16,688)
Ending Balance	(58,403)	(21,868)
Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	76,255
Ending Balance	134,547	76,255
Equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	98,123	13,368
Additions	94,827	84,755
Ending Balance	192,950	98,123
Equipment [Member] | Accumulated Amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance	(21,868)	(5,180)
Depreciation	(36,535)	(16,688)
Ending Balance	$ (58,403)	$ (21,868)

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 21, 2020	Jan. 31, 2023	Jan. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Purchase price in cash		$ 49,850	$ 333,369
MobileWellbeing ("MWB") [Member]
Disclosure of detailed information about intangible assets [line items]
Purchase price in cash	$ 25,000
Shares issued to acquire intangible assets	20,000
Additional shares issued to acquire intangible assets on ninetieth day of close	30,000
Consideration transferred for acquisition of intangible assets	$ 78,000
Percentage of royalty of gross sales	20%
Sales applicable to royalty	$ 2,500,000
Additional shares issued to acquire intangible assets on release of initial platforms	200,000
Amortization method		straight line
Estimated useful life intangible assets		5 years

Intangible Assets (Disclosure o

Intangible Assets (Disclosure of detailed information about purchase price allocation of intangible assets) (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Jul. 21, 2020	Jan. 31, 2023	Jan. 31, 2022
Consideration
Cash consideration on closing		$ 49,850	$ 333,369
Purchase Price allocation
Intangible assets		445,708	518,778
MobileWellbeing ("MWB") [Member]
Consideration
Cash consideration on closing	$ 25,000
Issued shares (50,000 shares issued at $1.06/share)	$ 53,000
Shares issued to acquire intangible assets, including closing	50,000
Shares issued to acquire intangible assets, value per share	$ 1.06
Total Consideration	$ 78,000
Purchase Price allocation
Intangible assets	78,000	$ 91,863	$ 119,571
Total Purchase Price allocation	$ 78,000

Intangible Assets (Disclosure_2

Intangible Assets (Disclosure of detailed information about intangible assets) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	$ 518,778
Intangible assets other than goodwill at end of period	445,708	$ 518,778
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	581,379	248,010
Additions	49,850	333,369
Intangible assets other than goodwill at end of period	631,229	581,379
Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	(62,601)	0
Amortization	(122,920)	62,601
Intangible assets other than goodwill at end of period	(185,521)	(62,601)
MWB [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	119,571
Intangible assets other than goodwill at end of period	91,863	119,571
MWB [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	138,561	91,970
Additions	0	46,591
Intangible assets other than goodwill at end of period	138,561	138,561
MWB [Member] | Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	(18,990)	0
Amortization	(27,708)	18,990
Intangible assets other than goodwill at end of period	(46,698)	(18,990)
IDSS [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	399,207
Intangible assets other than goodwill at end of period	353,845	399,207
IDSS [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	442,818	156,040
Additions	49,850	286,778
Intangible assets other than goodwill at end of period	492,668	442,818
IDSS [Member] | Accumulated amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period	(43,611)	0
Amortization	(95,212)	43,611
Intangible assets other than goodwill at end of period	$ (138,823)	$ (43,611)

Stock-based Compensation (Narra

Stock-based Compensation (Narrative) (Details)	12 Months Ended
	Jan. 31, 2023 CAD ($) Share $ / shares	Jan. 31, 2022 CAD ($) Share $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options authorized under stock option plan as a percentage of issued and outstanding common shares	10%
Number of options issued | Share	10,000,000	750,000
Vested stock-based compensation expense	$ 350,583	$ 182,996
Unvested stock-based compensation expense		16,438
Stock Options Granted in March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested stock-based compensation expense	1,834
Unvested stock-based compensation expense	0
Stock Options Granted in June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested stock-based compensation expense	6,778
Unvested stock-based compensation expense	0
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested stock-based compensation expense	7,826
Unvested stock-based compensation expense	$ 0
Stock Options Granted on January 13, 2023 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options issued | Share	10,000,000
Exercise price, share options granted | $ / shares	$ 0.05
Maximum term of options granted for share-based payment arrangement	four (4) years
Vested stock-based compensation expense	$ 334,145
Unvested stock-based compensation expense	$ 0
Stock Options Granted on July 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested stock-based compensation expense		34,246
Unvested stock-based compensation expense		0
Stock Options Granted on September 21, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested stock-based compensation expense		18,958
Unvested stock-based compensation expense		$ 0
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options issued | Share		250,000
Exercise price, share options granted | $ / shares		$ 0.36
Maximum term of options granted for share-based payment arrangement		one (1) year
Vested stock-based compensation expense		$ 50,675
Unvested stock-based compensation expense		$ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options issued | Share		250,000
Exercise price, share options granted | $ / shares		$ 0.345
Maximum term of options granted for share-based payment arrangement		18 months
Vested stock-based compensation expense		$ 48,672
Unvested stock-based compensation expense		$ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options issued | Share		250,000
Exercise price, share options granted | $ / shares		$ 0.25
Maximum term of options granted for share-based payment arrangement		18 months
Vested stock-based compensation expense		$ 30,445
Unvested stock-based compensation expense		$ 7,826

Stock-based Compensation (Discl

Stock-based Compensation (Disclosure of detailed information about options, valuation assumptions) (Details)	12 Months Ended
	Jan. 31, 2023 CAD ($) Year	Jan. 31, 2022 CAD ($) Year
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense		$ 16,438
Stock Options Granted in March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense	$ 0
Stock Options Granted in June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense	0
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense	$ 0
Stock Options Granted on January 13, 2023 [Member] | Directors, officers and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate	4%
Expected dividends	0%
Expected forfeiture rate	0%
Expected volatility	141%
Expected life | Year	4
Unvested stock-based compensation expense	$ 0
Stock Options Granted on July 17, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense		0
Stock Options Granted on September 21, 2020 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested stock-based compensation expense		$ 0
Stock Options Granted on March 23, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.26%
Expected dividends		0%
Expected forfeiture rate		0%
Expected volatility		134.30%
Expected life | Year		1
Unvested stock-based compensation expense		$ 1,834
Stock Options Granted on June 9, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.32%
Expected dividends		0%
Expected forfeiture rate		0%
Expected volatility		146.38%
Expected life | Year		1.5
Unvested stock-based compensation expense		$ 6,778
Stock Options Granted on July 30, 2021 [Member] | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free rate		0.38%
Expected dividends		0%
Expected forfeiture rate		0%
Expected volatility		131.33%
Expected life | Year		1.5
Unvested stock-based compensation expense		$ 7,826

Stock-based Compensation (Dis_2

Stock-based Compensation (Disclosure of number and weighted average exercise prices of share options) (Details)	12 Months Ended
	Jan. 31, 2023 Share $ / shares	Jan. 31, 2022 Share $ / shares
Disclosure Of Share Based Compensation [Abstract]
Number of options outstanding, beginning of period | Share	1,100,000	9,095,000
Number of options, granted | Share	10,000,000	750,000
Number of options, expired | Share	(70,000)	(4,776,250)
Number of options, expired | Share	(200,000)
Number of options, expired | Share	(250,000)
Number of options, expired | Share	(250,000)
Number of options, exercised | Share		(3,968,750)
Number of options outstanding, end of period | Share	10,330,000	1,100,000
Weighted average exercise price outstanding, beginning of period | $ / shares	$ 0.42	$ 0.18
Weighted average exercise price, granted | $ / shares	0.05	0.32
Weighted average exercise price, expired | $ / shares	0.54	0.17
Weighted average exercise price, expired | $ / shares	0.54
Weighted average exercise price, expired | $ / shares	0.36
Weighted average exercise price, expired | $ / shares	0.35
Weighted average exercise price, exercised | $ / shares		0.15
Weighted average exercise price outstanding, end of period | $ / shares	$ 0.06	$ 0.42

Stock-based Compensation (Dis_3

Stock-based Compensation (Disclosure of number and weighted average remaining contractual life of outstanding share options) (Details)	12 Months Ended
	Jan. 31, 2023 Share $ / shares	Jan. 31, 2022 Share	Jan. 31, 2021 Share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	10,330,000	1,100,000	9,095,000
Exercisable	10,330,000
Exercise Price | $ / shares	$ 0.06
Remaining Life (Years)	3 years 10 months 9 days
July 17, 2025 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	80,000
Exercisable	80,000
Exercise Price | $ / shares	$ 1.02
Remaining Life (Years)	2 years 5 months 15 days
Expiry Date	July 17, 2025
July 30, 2023 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	250,000
Exercisable	250,000
Exercise Price | $ / shares	$ 0.25
Remaining Life (Years)	6 months
Expiry Date	July 30, 2023
January 13, 2027 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding	10,000,000
Exercisable	10,000,000
Exercise Price | $ / shares	$ 0.05
Remaining Life (Years)	3 years 11 months 12 days
Expiry Date	January 13, 2027

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details)									12 Months Ended
	Nov. 30, 2022 CAD ($) shares	Nov. 07, 2022 CAD ($) shares	Nov. 01, 2022 CAD ($) $ / shares shares	Oct. 31, 2022 CAD ($) shares	Oct. 24, 2022 CAD ($) shares	Sep. 30, 2022 CAD ($) shares	Aug. 22, 2022 CAD ($) $ / shares shares	Mar. 05, 2021 CAD ($) $ / shares shares	Jan. 31, 2023 CAD ($) Share $ / shares shares	Jan. 31, 2022 CAD ($) Share $ / shares shares	Jan. 31, 2021 shares
Disclosure of classes of share capital [line items]
Number of shares issued | shares									122,051,292
Number of shares outstanding | shares									122,051,292	109,051,292	101,717,973
Proceeds from issuance of units									$ 495,000	$ 1,090,085
Share issue related cost									33,200	$ 3,770
Number of share options exercised | Share										3,968,750
Exercise price of share options exercised | $ / shares										$ 0.15
Proceeds from exercise of options									$ 0	$ 595,313
Number of shares issued for services | shares	200,000	1,000,000		200,000	300,000	200,000	1,200,000		250,000
Fair value of shares issued for services	$ 7,000	$ 50,000		$ 9,000	$ 15,000	$ 12,000	$ 72,000		$ 36,250
Exercise of options										595,313
Share subscriptions received									$ 50,000	0
Number of shares issued for subscription | shares									1,000,000
Par value per share | $ / shares									$ 0.05
Share-based payment reserve [Member]
Disclosure of classes of share capital [line items]
Exercise of options										$ (361,284)
Warrant reserve [Member]
Disclosure of classes of share capital [line items]
Share issue related cost									$ 8,632
Option Exercise One [Member]
Disclosure of classes of share capital [line items]
Number of share options exercised | Share									3,968,750
Exercise price of share options exercised | $ / shares									$ 0.15
Proceeds from exercise of options									$ 595,313
Option Exercise One [Member] | Share-based payment reserve [Member]
Disclosure of classes of share capital [line items]
Exercise of options									$ 361,284
Private Placement [Member]
Disclosure of classes of share capital [line items]
Number of units issued | shares								3,114,569
Units issued price per unit | $ / shares								$ 0.35
Proceeds from issuance of units								$ 1,090,085
Exercise price of warrants exercisable | $ / shares								$ 0.5
Term of warrants								24 months
Expected dividend yield of warrants granted								0%
Risk free interest rate, warrants granted								0.29%
Expected volatility of warrans granted								131%
Expected life of warrants granted								2 years
Fair value of warrants issued								$ 394,681
Fair value of common shares issued								695,404
Share issue related cost								$ 3,770
Private Placement [Member] | Tranche One [Member]
Disclosure of classes of share capital [line items]
Number of units issued | shares							8,300,000
Units issued price per unit | $ / shares							$ 0.05
Proceeds from issuance of units							$ 415,000
Exercise price of warrants exercisable | $ / shares							$ 0.1
Term of warrants							24 months
Expected dividend yield of warrants granted							0%
Risk free interest rate, warrants granted							3.49%
Expected volatility of warrans granted							101.42%
Expected life of warrants granted							2 years
Fair value of common shares issued							$ 331,170
Share issue related cost							33,200
Private Placement [Member] | Final Tranche [Member]
Disclosure of classes of share capital [line items]
Number of units issued | shares			1,600,000
Units issued price per unit | $ / shares			$ 0.05
Proceeds from issuance of units			$ 80,000
Exercise price of warrants exercisable | $ / shares			$ 0.1
Term of warrants			24 months
Expected dividend yield of warrants granted			0%
Risk free interest rate, warrants granted			3.91%
Expected volatility of warrans granted			102.40%
Expected life of warrants granted			2 years
Fair value of common shares issued			$ 68,792
Private Placement [Member] | Warrant reserve [Member] | Tranche One [Member]
Disclosure of classes of share capital [line items]
Fair value of warrants issued							$ 83,830
Number of warrants issued | shares							4,150,000
Private Placement [Member] | Warrant reserve [Member] | Final Tranche [Member]
Disclosure of classes of share capital [line items]
Fair value of warrants issued			$ 11,208
Number of warrants issued | shares			800,000

Capital Stock (Disclosure of co

Capital Stock (Disclosure of continuity of warrants) (Details)	12 Months Ended
	Jan. 31, 2023 Share $ / shares	Jan. 31, 2022 Share $ / shares
Disclosure of classes of share capital [abstract]
Number of warrants outstanding at beginning of period | Share	3,114,569	1,548,000
Number of warrants issued | Share	4,150,000	3,114,569
Number of warrants issued | Share	800,000
Number of warrants expired | Share	0	(1,548,000)
Number of warrants outstanding at end of period | Share	8,064,569	3,114,569
Weighted average exercise price at beginning of period | $ / shares	$ 0.5	$ 0.5
Weighted average exercise price issued | $ / shares	0.1	0.5
Weighted average exercise price issued | $ / shares	0.1
Weighted average exercise price expired | $ / shares	0	0.5
Weighted average exercise price at ending of period | $ / shares	$ 0.25	$ 0.5

Capital Stock (Disclosure of nu

Capital Stock (Disclosure of number, exercise price and remaining life of outstanding warrants) (Details)	12 Months Ended
	Jan. 31, 2023 Share $ / shares	Jan. 31, 2022 Share $ / shares	Jan. 31, 2021 Share $ / shares
Disclosure of classes of share capital [line items]
Warrants Outstanding | Share	8,064,569	3,114,569	1,548,000
Exercise Price | $ / shares	$ 0.25	$ 0.5	$ 0.5
Remaining Life (Years)	1 year 3 days
Warrants Outstanding Expired On March 5, 2023 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding | Share	3,114,569
Exercise Price | $ / shares	$ 0.5
Remaining Life (Years)	1 month 2 days
Expiry Date	Mar. 05, 2023
Warrants Outstanding Expired On August 22, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding | Share	4,150,000
Exercise Price | $ / shares	$ 0.1
Remaining Life (Years)	1 year 6 months 21 days
Expiry Date	Aug. 22, 2024
Warrants Outstanding Expired On November 1, 2024 [Member]
Disclosure of classes of share capital [line items]
Warrants Outstanding | Share	800,000
Exercise Price | $ / shares	$ 0.1
Remaining Life (Years)	1 year 9 months
Expiry Date	Nov. 01, 2024

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of transactions between related parties [line items]
Marketing expenses	$ 294,056	$ 508,609
Due to related parties	197,108	0
CEO [Member]
Disclosure of transactions between related parties [line items]
Marketing expenses	149,000	127,000
Advanced to CEO	$ 12,995	$ 12,995

Related Party Transactions (Dis

Related Party Transactions (Disclosure of transactions with key management personnel ) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of transactions between related parties [line items]
Management fees	$ 282,010	$ 269,845
Rent	35,901	32,147
Key management personnel compensation	342,010	334,345
CEO [Member]
Disclosure of transactions between related parties [line items]
Management fees	120,000	109,500
Vehicle expense	18,000	18,000
Rent	24,000	28,500
COO [Member]
Disclosure of transactions between related parties [line items]
Management fees	102,000	92,000
Vehicle expense	18,000	18,000
CFO [Member]
Disclosure of transactions between related parties [line items]
Management fees	$ 60,010	$ 68,345

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details)	Jul. 01, 2022 CAD ($)
CEO [Member]
Disclosure of transactions between related parties [line items]
Monthly compensation	$ 10,000
Monthly rent obligation	2,000
Personal vehicle obligation	1,500
COO [Member]
Disclosure of transactions between related parties [line items]
Monthly compensation	8,500
Personal vehicle obligation	$ 1,500

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 79,250	$ 211,302
Credit risk [Member] | One customer [Member]
Disclosure of detailed information about financial instruments [line items]
Percentage of revenue	95%	100%
Percentage of accounts receivable	86%	100%
Liquidity risk [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 79,250	$ 211,302
Current liabilities	$ 871,124	$ 349,672

Capital Management (Narrative)

Capital Management (Narrative) (Details) - CAD ($)	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Disclosure Of Capital Management [Abstract]
Shareholders' equity	$ (153,389)	$ 886,985	$ 868,289

Business Segment and Concentr_2

Business Segment and Concentration (Narrative) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Disclosure of operating segments [line items]
Property and equipment	$ 134,547	$ 76,255
India [Member]
Disclosure of operating segments [line items]
Property and equipment	$ 53,374	$ 76,255
Credit risk [Member] | One customer [Member]
Disclosure of operating segments [line items]
Percentage of revenue	95%	100%
Percentage of accounts receivable	86%	100%

Income Taxes - (Disclosure of d

Income Taxes - (Disclosure of detailed information about effective income tax expense (recovery)) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Major components of tax expense (income) [abstract]
Loss for the period	$ (2,067,757)	$ (1,882,178)
Tax rate	27%	27%
Expected income tax recoverable at statutory rate	$ (558,000)	$ (508,000)
Change due to acquisition, tax rates, and other	0	0
Non-deductible items	95,000	54,000
Share issuance costs	(7,000)	(1,000)
Expired non-capital losses		0
Change in unrecognized deductible temporary differences	470,000	455,000
Total income tax recovery	$ 0	$ 0

Income Taxes - (Disclosure of_2

Income Taxes - (Disclosure of detailed information about deferred tax assets) (Details) - CAD ($)	Jan. 31, 2023	Jan. 31, 2022
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	$ 2,215,000	$ 1,856,000
Less: Unrecognized deferred tax assets	(2,215,000)	(1,856,000)
Net deferred tax assets	0	0
Non-capital losses available for future period [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	2,159,000	1,821,000
Share issuance costs [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	11,000	13,000
Property equipment and intangible assets [Member]
Disclosure Of Information About Income Taxes [Line Items]
Total deferred tax assets	$ 45,000	$ 22,000

Income Taxes - (Disclosure of_3

Income Taxes - (Disclosure of detailed information about unrecognized temporary differences and tax losses) (Details) - CAD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Non-capital losses [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 7,995,200	$ 6,745,000
Temporary differences, expiry period	2027 - 2043	2027 - 2043
Share issuance costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 41,000	$ 47,000
Temporary differences, expiry period	2043 - 2047	2043 - 2047
Property equipment and intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Temporary differences	$ 168,000	$ 84,000
Temporary differences, expiry period	No expiry	No expiry

Promissory note (Narrative) (De

Promissory note (Narrative) (Details) - Promissory Note [Member] - CAD ($)	Jan. 31, 2023	Dec. 12, 2022
Disclosure Of Detailed Information About Borrowings Line Items
Issue of promissory note		$ 35,000
Interest		59.90%
Accrued interest	$ 2,870

Subsequent events (Narrative) (

Subsequent events (Narrative) (Details)

1 Months Ended

12 Months Ended

Nov. 30, 2022 shares

Nov. 07, 2022 shares

Oct. 31, 2022 shares

Oct. 24, 2022 shares

Sep. 30, 2022 shares

Aug. 22, 2022 shares

May 25, 2023 shares

Mar. 28, 2023 Share $ / shares

Feb. 23, 2023 Share $ / shares

Feb. 13, 2023 CAD ($) $ / shares shares

Jan. 31, 2023 Share $ / shares shares

Jan. 31, 2022 Share $ / shares

Disclosure of non-adjusting events after reporting period [line items]

Shares issued upon exercise of options | Share

3,968,750

Number of options issued | Share

10,000,000

750,000

Weighted average exercise price of options granted

$ 0.05

$ 0.32

Number of shares issued for services | shares

200,000

1,000,000

200,000

300,000

200,000

1,200,000

250,000

Subsequent Event [Member]

Disclosure of non-adjusting events after reporting period [line items]

Shares issued upon exercise of options | Share

500,000

Exercise price of share options exercised

$ 0.05

Subsequent Event [Member] | Non-brokered private placement [Member]

Disclosure of non-adjusting events after reporting period [line items]

Proceeds from issuing units | $

$ 612,500

Number of units issued | shares

12,250,000

Units issued price per unit

$ 0.05

Term of warrants

2 years

Exercise price of warrants

$ 0.1

Consultant [Member] | Subsequent Event [Member]

Disclosure of non-adjusting events after reporting period [line items]

Number of options issued | Share

600,000

Weighted average exercise price of options granted

$ 0.15

Number of shares issued for services | shares

335,000